drugset / Trial / NCT07472933
Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This study aims to observe the efficacy and safety of the combination of vebecotototo monoclonal antibody and putli monoclonal antibody in the treatment of EGFR-positive refractory biliary malignant tumors.
Timeline
- Start
- 2026-08-01
- Primary completion
- 2028-02-29
- Completion
- 2028-02-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Putilimab | Unknown | 200 mg | Intravenous |
| Subject | Vibecotecotamab | Unknown | 2 mg/kg | Intravenous |